Dies ist eine HTML Version eines Anhanges der Informationsfreiheitsanfrage 'Comunicaciones DG SANTE - Gobierno de España'.




       
2020
, 2020
27 October
vaccination 
ation 
G Collabor
A
NIT
behalf of the EU/EEA 
 on 
27 October 2020
ialogue meeting held 23 October, 
d

State of play with national  strategies in the EU/EEA and the UK  –
HSC Meeting, 




 
tee  ork
rs 
bers 
2018
2
to w ECDC 
mbe
em )
ners
29)
m
in 
=2
e me (n=
ve   (n
5 MS 
Key part
Activ
Passi
authorised in 
Steering Commit from  closely with  Secretariat
formed 
methodology 
oups  vaccines 
on 
ature  evidence-based 
EE
FI
DK
FR
DE
CZ
the liter
GR
WG N
CY
Technical Advisory Gr
HU
HR
IS
**
BU
9
IE
sation 
WG 3
-1
group 
BE
following standard 
COVID
C
IT
evidence in 
D
AT
etariat
EC
LI
ety, 
*
 
UK
secr
Immuni
LV
saf
WG 2 FLU child
SE
LT
ES
and 
LU
 
SI
lt
MT
SK
WG 1 FLU adu
NL
RO
NO
PT
PL
eness 
EU/EEA National 
fectiv
, ef
or 
y and summarize scientific 
EU 
ure f
at
E)
D
ficacy
liter ety for  s (
ibuting
  n
to identif
iew of  and saf vaccine
ation between 
O  /HQ
is 
ropean
O
-19 
WH
ic rev
Eu mmissio
at eness  ID
EU incl. ef
Co
EUR RNN/GNN
alth is contr
iv
 
He em fect
cy
st
d COV
oint 
Collabor Focus  the 
, ef ise
EU/EEA NITAG Collaboration 
ropean
ction on 
Public 
Eu Medicines  Agen
EC/J A accination
ive sy


V

ficacy
*U ** L ef author




3
in 
prioritise 
will be 
to 
accinated 
der 
systems 
plans 
under 
and acceptance
be v
or
to 
ed…
er
eness 
in short supply?
currently 
are 
deliv
monitoring  ectiv
y groups 
eff
vaccines 
and by whom in 
will be 
ety, 
vaccines 
ed 
-specific 
for priorit
, saf
oduct age
EU/EEA MS and the UK
when 
accines 
or COVID-19 
een consider
how v
how pr
ailable?
e b
on 
on 
plan f
accine cover
accination?
ate: 21/31 
recommendations  the campaigns 
for v
already av
of 
ormation 
ormation 
will be/hav
deployment 
eloped 
oups 
document v
of country vaccination preparedness 
phases 
gr
ovide inf
ovide inf to 
Response r
accine 
evidence  get 
e you dev
Is a v development or 
Hav the initial 
What  the tar
Please pr
Please pr organised 
Overview  collected 









4
of 
all 
for 
almost 
unknowns;

plans
ailable in 
the man
av
to 
be 
recommendations 
due 
meeting; 
interim 
preparedness 
eloped 
dialogue 
in all countries 
dev
the 
ess 
ogr
plans were mentioned to 
in pr
further and 
vaccination 
e come  vaccinated first:
countries attending 
be 
er, it is still work 
ul hav
Vaccination preparedness  the 21/31 
Howev
A handf groups to 
Availability of 







5
ailable 
comorbidities, 
av
ers
due to 
workers
work
home 
determined)
disease 
to be 
erent definitions 
social care 

based
and care 
diff
age 
riorit
home 
(p
e facilities/institutions
health and 
severe COVID-19  car
in a care  and 
social workers, 
advice is entirely 
adults 
mentioned
and 
of the population 
65+)* 
long-term 
interim 
Older  All those 80+  All those 75+ All those 70+
All those 65+ All those 60+ All those 55+
All those 50+ Rest 
(60+, 









with higher risk of 
*UK 
esidents in 
care workers 
being r
Health 
Older people 
Individuals  or 
Priority groups 







at 
6
accine  as well 
oups 
(e.g. on 
vaccines 
e on gr
reported v
data 
of 
atur
liter
ears will accept 
including  acteristics 
>64 y
om the 
fr COVID-19;
vaccination; 
country specific 
, char
 of 
3 studies,  oup
due to 
gr
individuals 
ormation 
of 
for prioritisation and 
impact of 
get 
analysis inf
om phase  tar
and death 
et groups when needed
fr
data,  y) and 
ansparency;
(only 54% 
targ
eillance 
disease 
of 
ormation 
mortalit
inf
airness, tr
be considered 
modelling assessing 
severe 
Finland)
efficacy by age and  y; 
assessments 
justice, f
y, 
ety and  vailabilit
Mathematical 
Vaccine-specific  saf as a
Epidemiological surv hospitalization and  higher risk of 
Equit
Acceptance  vaccination in 
Evidence to  reprioritisation 









7
seasonal 
for 
chain 
additional 
COVID-19  or 
vaccination 
and cold  about  need f
ery services 
COVID-19 
deliv
ansport  ormation  potential 
e inf
incl.   out of 
the 
age, tr

es  oll 
 stor as mor
servic

for the r
ailable i.e.
ery 
vaccine assesse
deliv
that  be 
chain.
become av e cold 
and structures 
accination 
esponded 
atur
will need to  acteristics 
vaccines 
existing v
countries r ements 
a low temper
Use of  influenza  plans;
Some  requir vaccine char ultr
Logistical considerations 






 
8
 
    
countries. 
erse 
groups
-2 
adv
ocus 
         
for COVID-19 
possible 
in all EU/EEA 
SARS-CoV

vestigated.
registries 
for 
in
surveys/f
egistries: 
be 
rates 
place: 
available 
indemnif
immunisation 
in 
ound 
onic 
law to 
Acceptance in 
immunisation r
age 
detection 

ackgr
ed 
onic 
cover
y. B
ral populations to 

studies/ 
ad hoc electr
for 
signal 
in 
electr
gene
 propos
in 
for coverage, safety, 
using 
systems 
oduct liabilit
est 
pr
assessed 
inter
ently considering 
be 
erage 
ond 
curr
or 
ety reporting with 
, MoH in 
special 
eloping 
outine saf
ents of 
ectiveness to 
monitoring: 
Monitoring cov
Countries with other 
R
In October
vaccinated bey
ev
Eff
Monitoring system  effectiveness and acceptance




*Countries dev vaccine